PMID- 16945819
OWN - NLM
STAT- MEDLINE
DCOM- 20070216
LR  - 20181201
IS  - 1553-8389 (Print)
IS  - 1878-0938 (Linking)
VI  - 7
IP  - 3
DP  - 2006 Jul-Sep
TI  - Bivalirudin versus unfractionated heparin in patients undergoing percutaneous 
      coronary intervention after acute myocardial infarction.
PG  - 132-5
AB  - BACKGROUND: Bivalirudin is replacing heparin as the anticoagulant agent of choice 
      for elective percutaneous coronary intervention (PCI). This study aimed to assess 
      the safety and clinical outcomes of bivalirudin versus unfractionated heparin 
      (UFH) in patients undergoing PCI for acute myocardial infarction (AMI). METHODS: 
      A cohort of 672 consecutive patients presenting with AMI without prior 
      thrombolytic therapy were treated with either bivalirudin (216 patients) or UFH 
      (456 patients). Platelet glycoprotein IIb/IIIa inhibitors were administered at 
      the operator's discretion. The in-hospital, 30-day, and 6-month outcomes of the 
      two groups were compared. RESULTS: Baseline clinical and angiographic 
      characteristics were similar between the groups. In-hospital complications were 
      similar, although there was a trend of a less major hematocrit drop in the 
      bivalirudin group (0.9% vs. 3.1%, P=.09). All clinical outcomes were similar 
      between the groups at 30-day and 6-month follow-ups. There was no statistical 
      significance for acute thrombosis and subacute thrombosis between the groups, and 
      there was no late thrombosis from either group. The event-free survival rate was 
      similar between the groups (P=.41). CONCLUSION: The use of bivalirudin in 
      patients undergoing PCI after AMI is safe and feasible. Bivalirudin should be 
      considered as an alternative anticoagulant agent during PCI to treat patients 
      presenting with AMI.
FAU - Chu, William W
AU  - Chu WW
AD  - Division of Cardiology, Washington Hospital Center, Washington, DC, USA.
FAU - Kuchulakanti, Pramod K
AU  - Kuchulakanti PK
FAU - Wang, Betty
AU  - Wang B
FAU - Torguson, Rebecca
AU  - Torguson R
FAU - Clavijo, Leonardo C
AU  - Clavijo LC
FAU - Pichard, Augusto D
AU  - Pichard AD
FAU - Suddath, William O
AU  - Suddath WO
FAU - Satler, Lowell F
AU  - Satler LF
FAU - Kent, Kenneth M
AU  - Kent KM
FAU - Waksman, Ron
AU  - Waksman R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Cardiovasc Revasc Med
JT  - Cardiovascular revascularization medicine : including molecular interventions
JID - 101238551
RN  - 0 (Anticoagulants)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary/adverse effects
MH  - Anticoagulants/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Angiography
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Heparin/*analogs & derivatives/*therapeutic use
MH  - Hirudins
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnostic imaging/*therapy
MH  - Peptide Fragments/*therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors/therapeutic use
MH  - Postoperative Complications/diagnostic imaging/etiology
MH  - Recombinant Proteins/therapeutic use
MH  - Research Design
MH  - Ticlopidine/analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2006/09/02 09:00
MHDA- 2007/02/17 09:00
CRDT- 2006/09/02 09:00
PHST- 2006/04/07 00:00 [received]
PHST- 2006/04/07 00:00 [accepted]
PHST- 2006/09/02 09:00 [pubmed]
PHST- 2007/02/17 09:00 [medline]
PHST- 2006/09/02 09:00 [entrez]
AID - S1553-8389(06)00143-6 [pii]
AID - 10.1016/j.carrev.2006.04.005 [doi]
PST - ppublish
SO  - Cardiovasc Revasc Med. 2006 Jul-Sep;7(3):132-5. doi: 
      10.1016/j.carrev.2006.04.005.